Trial · NCT04253236
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Responders at Week 13 | Cohort 1: RVT-1401 680 mg/Week | 1 | Participants | ||
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death | Cohort 1: RVT-1401 680 mg/Week | TEAEs | 5 | Participants | |
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death | Cohort 1: RVT-1401 680 mg/Week | SAEs | 1 | Participants | |
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death | Cohort 1: RVT-1401 680 mg/Week | Treatment-related AEs | 4 | Participants | |
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death | Cohort 1: RVT-1401 680 mg/Week | Deaths | 0 | Participants | |
| Time to Response | Cohort 1: RVT-1401 680 mg/Week | 3 | Weeks | ||
| Time to Achieving Hb Levels in the Normal Range | Cohort 1: RVT-1401 680 mg/Week | 5 | Weeks | ||
| Number of Participants With Change in Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-F) Score | Cohort 1: RVT-1401 680 mg/Week | 3 | Participants | ||
| Number of Participants With Change in Medical Research Council (MRC) Breathlessness Scale | Cohort 1: RVT-1401 680 mg/Week | 4 | Participants | ||
| Number of Participants With Change in Euro Quality-5 Dimension-3 Level (EQ-5D-3L) Score | Cohort 1: RVT-1401 680 mg/Week | 4 | Participants | ||
| Concentration of RVT-1401 Pre-dose | Cohort 1: RVT-1401 680 mg/Week | NA | Geometric Coefficient of Variation NA | Milligrams per liter | |
| Number of Participants With Presence of Anti-RVT 1401 Antibodies | Cohort 1: RVT-1401 680 mg/Week | 0 | Participants | ||
| Number of Participants With Change in Levels of Total Immunoglobulin (Ig)G and IgG Subclasses (1-4) | Cohort 1: RVT-1401 680 mg/Week | Total IgG | 5 | Participants | |
| Number of Participants With Change in Levels of Total Immunoglobulin (Ig)G and IgG Subclasses (1-4) | Cohort 1: RVT-1401 680 mg/Week | IgG Subclasses (1-4) | 5 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04253236/results